Lung Cancer (NSCLC)BMINCT07906626
Snakehead Fish Extract and Curcumin Co-Supplementation in Advanced Lung Cancer on Inflammation, Nutritional Status, and Quality of Life
A study testing Snakehead Fish Extract and Curcumin in people with Lung Cancer (NSCLC), run by Universitas Sumatera Utara at 1 site in Indonesia.
Trial summary
Background: Patients with advanced lung cancer receiving systemic therapy often experience nutritional decline, systemic inflammation, and impaired quality of life. Channa striata extract and Curcumin may offer complementary nutritional and anti-inflammatory support, but clinical evidence for their combination is… Read more about this study
- Who is it for?
- Ages 40 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Lung Cancer (NSCLC)
- What is being tested?
- Snakehead Fish Extract and Curcumin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteIndonesia
- Study dates
- 1 Jul 2025to 1 Sep 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Patients with newly diagnosed non-small cell lung carcinoma
- Consuming a combination supplement containing snakehead fish extract and curcumin extract until the second cycle
- Aged 40-60 years
- No history of allergies to freshwater fish or snakehead fish
- No history of allergies to foods containing curcumin
- Willing to participate in the study
Who cannot join
- Lung cancer with performance status > 4
- BMI (Body Mass Index) < 18.5
- Mid-Upper Arm Circumference (MUAC) < 23.5
- Allergy to supplements consumed during the study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of a Routine Second Transurethral Resection of the Bladder (TURBT) After Primary Complete Blue Light TURBT in Patients With Non-muscle Invasive Intermediate- and High-risk Urothelial Bladder Cancer: a Prospective, Randomized, Multicenter Study
Background: Patients with advanced lung cancer receiving systemic therapy often experience nutritional decline, systemic inflammation, and impaired quality of life. Channa striata extract and Curcumin may offer complementary nutritional and anti-inflammatory support, but clinical evidence for their combination is limited.
The goal of this clinical trial is to learn if combined Channa striata (snakehead fish) extract and curcumin supplementation works to improve nutritional status, inflammation, and quality of life in adults with advanced lung cancer receiving systemic therapy. The main questions it aims to answer are:
Read more
- Does Channa striata extract plus curcumin co-supplementation raise body weight in participants with advanced lung cancer?
- Does this co-supplementation lower inflammatory markers in these participants?
- Does this co-supplementation improve health-related quality of life in these participants?
Researchers will compare participants taking Channa striata extract plus curcumin to participants taking a placebo (a look-alike capsule that contains no active ingredients) to see if the co-supplementation works.
Participants will:
- Take Channa striata extract plus curcumin capsules or placebo capsules 3 times daily for 9 weeks alongside their standard systemic therapy
- Have their body weight (kg), body mass index, and mid-upper arm circumference checked (cm)
- Give blood samples to test inflammatory markers
- Answer questionnaire questions about their health-related quality of life (QLQ -C30)
Read the detailed description
Patients with advanced lung cancer receiving systemic therapy frequently experience progressive weight loss, systemic inflammation, and impaired quality of life. Channa striata extract provides nutritional support rich in amino acids, while curcumin exerts anti-inflammatory properties. This study aims to evaluate whether the combination of Channa striata extract and curcumin as an adjunct to standard systemic therapy improves clinical and nutritional outcomes in adults with advanced lung cancer.
Participants receive either the combination supplement (3000 mg Channa striata extract and 300 mg curcumin daily) or a matching placebo for 9 weeks while continuing their standard systemic therapy. Clinical assessments are conducted at baseline and after 9 weeks to evaluate changes in body weight, nutritional status (body mass index and mid-upper arm circumference), systemic inflammatory markers (C-reactive protein, TNF-alpha, and IL-6), and health-related quality of life.
- Conditions
- Lung Cancer (NSCLC)
- Being tested
- Snakehead Fish Extract and Curcumin
- Keywords
- lung cancer, Channa striata, Curcumin, Body Weight, Inflammation markers, Quality of Life
- Medical subject headings
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Body Weight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Snakehead Fish Extract and CurcuminDrug
Participants in the intervention group received 2 capsules 3 times daily for 3 months (9 Weeks). Each capsule contained 500 mg of Channa striata extract and 50 mg of curcumin (Striatamin®; PT Mega Medica, Jakarta, Indonesia), providing a total daily dose of 3000 mg of C. striata extract and 300 mg of curcumin.
| Study group | Role | What they receive |
|---|---|---|
| INTERVENTION | Experimental | Not described Receives: Drug: Snakehead Fish Extract and Curcumin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in body weight at 9 weeks
Body weight is measured in kilograms (kg) using a calibrated digital health scale at baseline and after 9 weeks of intervention. The metric is calculated as the post-intervention value minus the baseline value.
Measured: Baseline and After 9 weeks
Secondary outcomes (8)
Change from baseline in serum C-reactive protein (CRP) levels at 9 weeks
Serum CRP levels are measured from venous blood samples using enzyme-linked immunosorbent assay (ELISA) and expressed in milligrams per deciliter (mg/dL).
Measured: Baseline and After 9 weeks
Change from baseline in serum tumor necrosis factor-alpha (TNF-alpha) levels at 9 weeks
Serum TNF-alpha levels are measured from venous blood samples using enzyme-linked immunosorbent assay (ELISA) and expressed in picograms per milliliter (pg/mL).
Measured: Baseline and After 9 weeks
Change from baseline in serum interleukin-6 (IL-6) levels at 9 weeks
Serum IL-6 levels are measured from venous blood samples using enzyme-linked immunosorbent assay (ELISA) and expressed in picograms per milliliter (pg/mL).
Measured: Baseline and After 9 weeks
Change from baseline in mid-upper arm circumference (MUAC) at 9 weeks
MUAC is measured in centimeters (cm) on the relaxed left arm at the midpoint between the acromion and olecranon process using a non-elastic measuring tape.
Measured: Baseline and After 9 weeks
Change from baseline in Body Mass Index (BMI) at 9 weeks
BMI is calculated as body weight in kilograms divided by height in meters squared (kg/m²).
Measured: Baseline and After 9 weeks
Change from baseline in EORTC QLQ-C30 functional scale scores at 9 weeks
Evaluates physical, role, emotional, cognitive, and social functioning using the EORTC QLQ-C30. Scores range from 0 to 100, where a higher score indicates a higher/better level of functioning.
Measured: Baseline and After 9 weeks
Change from baseline in EORTC QLQ-C30 symptom scale scores at 9 weeks
Evaluates symptoms including fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties. Scores range from 0 to 100, where a higher score indicates a higher level of symptoms or greater symptom burden.
Measured: Baseline and After 9 weeks
Change from baseline in EORTC QLQ-C30 global health status score at 9 weeks
Assessed using the Indonesian version of the EORTC QLQ-C30 questionnaire. Global health status scores range from 0 to 100, where a higher score represents a better overall quality of life and higher level of general health.
Measured: Baseline and After 9 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Oct 2026
- Study start1 Jul 2025
- Primary completion1 Jul 2026
- Study completion1 Sep 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Cancer (NSCLC)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- curcumin as an adjunct to chemotherapy in advanced lung cancer patients, this study employed a prospective, double-blind randomized controlled trial (RCT) design spanning three treatment cycles (9 weeks). Participant allocation was balanced equally (1:1 ratio) between the active supplement and placebo arms through a block randomization procedure (block size of 4) executed via the Researcher Randomizer tool (https://www.randomizer.org). To minimize selection bias, an independent investigator with no involvement in clinical evaluations or data analysis managed group assignments. Furthermore, eligible participants received sequential identification codes based on their registration sequence."Group allocation was performed by an independent researcher who was not involved in clinical assessment or data analysis to avoid the risk of selection bias. Each subject was assigned a unique identification number according to their enrolment order in the study. To preserve rigorous double-blind cond
- Masking
- None (open label)
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universitas Sumatera Utara
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Noni Novisari Soeroso, Universitas Sumatera Utara
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07906626
- Sponsor's protocol ID
- 541/KEPK/USU/2025
- Other IDs
- 23/UN5.4.10.K/PT.01.01.
- Acronym
- BMI
- Status last verified
- Jul 2025
- First submitted
- 15 Oct 2026
- Last updated
- 30 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The individual participant data (IPD) will not be shared to protect patient privacy and maintain the confidentiality of medical records, as approved by the Health Research Ethics Committee
Study at a glance
From the registry record, last updated by the sponsor on 30 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of a Routine Second Transurethral Resection of the Bladder (TURBT) After Primary Complete Blue Light TURBT in Patients With Non-muscle Invasive Intermediate- and High-risk Urothelial Bladder Cancer: a Prospective, Randomized, Multicenter Study
- ClinicalTrials.gov ID
- NCT07906626
- Acronym / sponsor ID
- BMI / 541/KEPK/USU/2025
- Conditions
- Lung Cancer (NSCLC)
- Keywords
- lung cancer, Channa striata, Curcumin, Body Weight, Inflammation markers, Quality of Life
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Universitas Sumatera UtaraUniversity, hospital or other
- Study start
- 1 Jul 2025 (actual)
- Primary completion
- 1 Jul 2026 (actual)
- Study completion
- 1 Sep 2026 (actual)
- First posted
- 30 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: Patients with advanced lung cancer receiving systemic therapy often experience nutritional decline, systemic inflammation, and impaired quality of life. Channa striata extract and Curcumin may offer complementary nutritional and anti-inflammatory support, but clinical evidence for their combination is limited.
The goal of this clinical trial is to learn if combined Channa striata (snakehead fish) extract and curcumin supplementation works to improve nutritional status, inflammation, and quality of life in adults with advanced lung cancer receiving systemic therapy. The main questions it aims to answer are:
- Does Channa striata extract plus curcumin co-supplementation raise body weight in participants with advanced lung cancer?
- Does this co-supplementation lower inflammatory markers in these participants?
- Does this co-supplementation improve health-related quality of life in these participants?
Researchers will compare participants taking Channa striata extract plus curcumin to participants taking a placebo (a look-alike capsule that contains no active ingredients) to see if the co-supplementation works.
Participants will:
- Take Channa striata extract plus curcumin capsules or placebo capsules 3 times daily for 9 weeks alongside their standard systemic therapy
- Have their body weight (kg), body mass index, and mid-upper arm circumference checked (cm)
- Give blood samples to test inflammatory markers
- Answer questionnaire questions about their health-related quality of life (QLQ -C30)
Detailed description
Patients with advanced lung cancer receiving systemic therapy frequently experience progressive weight loss, systemic inflammation, and impaired quality of life. Channa striata extract provides nutritional support rich in amino acids, while curcumin exerts anti-inflammatory properties. This study aims to evaluate whether the combination of Channa striata extract and curcumin as an adjunct to standard systemic therapy improves clinical and nutritional outcomes in adults with advanced lung cancer.
Participants receive either the combination supplement (3000 mg Channa striata extract and 300 mg curcumin daily) or a matching placebo for 9 weeks while continuing their standard systemic therapy. Clinical assessments are conducted at baseline and after 9 weeks to evaluate changes in body weight, nutritional status (body mass index and mid-upper arm circumference), systemic inflammatory markers (C-reactive protein, TNF-alpha, and IL-6), and health-related quality of life.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- curcumin as an adjunct to chemotherapy in advanced lung cancer patients, this study employed a prospective, double-blind randomized controlled trial (RCT) design spanning three treatment cycles (9 weeks). Participant allocation was balanced equally (1:1 ratio) between the active supplement and placebo arms through a block randomization procedure (block size of 4) executed via the Researcher Randomizer tool (https://www.randomizer.org). To minimize selection bias, an independent investigator with no involvement in clinical evaluations or data analysis managed group assignments. Furthermore, eligible participants received sequential identification codes based on their registration sequence."Group allocation was performed by an independent researcher who was not involved in clinical assessment or data analysis to avoid the risk of selection bias. Each subject was assigned a unique identification number according to their enrolment order in the study. To preserve rigorous double-blind cond
| Arm | Type | Receives |
|---|---|---|
| INTERVENTION | Experimental | Drug: Snakehead Fish Extract and Curcumin |
Who may qualify
- Ages
- 40 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Patients with newly diagnosed non-small cell lung carcinoma
- Consuming a combination supplement containing snakehead fish extract and curcumin extract until the second cycle
- Aged 40-60 years
- No history of allergies to freshwater fish or snakehead fish
- No history of allergies to foods containing curcumin
Key exclusion criteria (4 listed)
- Lung cancer with performance status > 4
- BMI (Body Mass Index) < 18.5
- Mid-Upper Arm Circumference (MUAC) < 23.5
- Allergy to supplements consumed during the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Snakehead Fish Extract and CurcuminParticipants in the intervention group received 2 capsules 3 times daily for 3 months (9 Weeks). Each capsule contained 500 mg of Channa striata extract and 50 mg of curcumin (Striatamin®; PT Mega Medica, Jakarta, Indonesia), providing a total daily dose of 3000 mg of C. striata extract and 300 mg of curcumin. | Drug | INTERVENTION |
Primary outcome
Change from baseline in body weight at 9 weeks
Time frame: Baseline and After 9 weeks
Body weight is measured in kilograms (kg) using a calibrated digital health scale at baseline and after 9 weeks of intervention. The metric is calculated as the post-intervention value minus the baseline value.
8 secondary outcomes
Change from baseline in serum C-reactive protein (CRP) levels at 9 weeks
Time frame: Baseline and After 9 weeks
Change from baseline in serum tumor necrosis factor-alpha (TNF-alpha) levels at 9 weeks
Time frame: Baseline and After 9 weeks
Change from baseline in serum interleukin-6 (IL-6) levels at 9 weeks
Time frame: Baseline and After 9 weeks
Change from baseline in mid-upper arm circumference (MUAC) at 9 weeks
Time frame: Baseline and After 9 weeks
Change from baseline in Body Mass Index (BMI) at 9 weeks
Time frame: Baseline and After 9 weeks
Change from baseline in EORTC QLQ-C30 functional scale scores at 9 weeks
Time frame: Baseline and After 9 weeks
Change from baseline in EORTC QLQ-C30 symptom scale scores at 9 weeks
Time frame: Baseline and After 9 weeks
Change from baseline in EORTC QLQ-C30 global health status score at 9 weeks
Time frame: Baseline and After 9 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Oct 2026.
- Individual participant dataSharing planned: No. The individual participant data (IPD) will not be shared to protect patient privacy and maintain the confidentiality of medical records, as approved by the Health Research Ethics Committee
Related trials for Lung Cancer (NSCLC)
RecruitingPhase 3
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic
RecruitingObservational study
Real-World Outcomes of Sevabertinib in HER2-Mutant Advanced NSCLC: A Bidirectional Cohort Study
HER2-mutant Advanced Non-Small Cell Lung Cancer
Active, not recruitingPhase 2
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 2
Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer
Early Stage Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
RecruitingObservational study
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Multiple Myeloma, Lymphoma, Non-Hodgkin
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Snakehead Fish Extract and Curcumin in people with Lung Cancer (NSCLC), run by Universitas Sumatera Utara at 1 site in Indonesia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Indonesia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in body weight at 9 weeks (time frame: Baseline and After 9 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2026.